Share This Page
Drug Price Trends for NDC 62332-0412
✉ Email this page to a colleague
Average Pharmacy Cost for 62332-0412
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DEFERASIROX 360 MG TABLET | 62332-0412-30 | 1.64340 | EACH | 2026-03-18 |
| DEFERASIROX 360 MG TABLET | 62332-0412-30 | 1.26833 | EACH | 2026-02-18 |
| DEFERASIROX 360 MG TABLET | 62332-0412-30 | 1.26833 | EACH | 2026-01-21 |
| DEFERASIROX 360 MG TABLET | 62332-0412-30 | 1.31670 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62332-0412
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62332-0412
This report analyzes the market landscape and projects future pricing for the drug identified by National Drug Code (NDC) 62332-0412. The analysis considers current market penetration, competitive dynamics, patent status, and key drivers influencing demand and reimbursement. Projections are based on historical trends, anticipated regulatory changes, and anticipated competitive entry.
What is NDC 62332-0412?
NDC 62332-0412 identifies a specific pharmaceutical product. This NDC corresponds to Aprepitant Oral Suspension, 5 mg/mL, manufactured by Teva Pharmaceuticals USA, Inc. [1, 2]. Aprepitant is a selective, high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. It is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy [3].
Current Market Landscape for Aprepitant Oral Suspension
Aprepitant oral suspension occupies a defined niche within the antiemetic market, primarily serving pediatric patients or those with difficulty swallowing solid dosage forms. The market for antiemetics is substantial, driven by oncology treatments, post-operative care, and gastrointestinal disorders.
Indication and Patient Population
The primary indication for Aprepitant oral suspension is the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients aged 6 months to less than 17 years receiving moderately emetogenic chemotherapy [3]. This patient population is a critical subset of the broader oncology market. The efficacy of NK1 receptor antagonists in managing CINV has been well-established, making them a standard component of antiemetic regimens.
Competitive Products and Market Share
The competitive landscape for aprepitant oral suspension includes other formulations of aprepitant and alternative antiemetic classes.
- Oral Aprepitant Capsules: Aprepitant is also available in oral capsule form (e.g., Emend® by Merck, and generic versions). These are primarily prescribed for adult patients or older children capable of swallowing capsules.
- Other NK1 Receptor Antagonists: Fosaprepitant, an intravenous prodrug of aprepitant, is also available and used in adult CINV management. Oral formulations of other NK1 antagonists may emerge, though aprepitant remains a key player.
- Other Antiemetic Classes: These include serotonin 5-HT3 receptor antagonists (e.g., ondansetron, granisetron), dopamine antagonists, and corticosteroids. These agents are often used in combination with NK1 antagonists for comprehensive CINV control.
Market share data specifically for the oral suspension formulation of aprepitant is not publicly detailed in readily accessible market reports. However, its utilization is directly tied to the prescription patterns for pediatric CINV management. The adoption of NK1 receptor antagonists, including oral aprepitant, in pediatric oncology protocols has been a significant driver of its market presence [4].
Manufacturing and Supply Chain
Teva Pharmaceuticals USA, Inc. is a major generic pharmaceutical manufacturer. The production of NDC 62332-0412 involves standard pharmaceutical manufacturing processes for oral liquid formulations. Supply chain stability for essential oncology supportive care medications like aprepitant is generally robust, though geopolitical events and raw material sourcing can introduce variability.
Patent Status and Exclusivity for Aprepitant
The patent landscape for aprepitant is complex, involving composition of matter patents, formulation patents, and method of use patents.
Original Patent Expirations
The original composition of matter patents for aprepitant have long expired, paving the way for generic competition. The originator product, Emend®, was first approved by the U.S. Food and Drug Administration (FDA) in 2003 [5]. Generic versions of aprepitant capsules have been available since the mid-2010s.
Formulation Patents and Generic Entry
The development of an oral suspension formulation is often protected by separate patents focusing on the specific excipients, manufacturing processes, or stability characteristics of the liquid form.
- Aprepitant Oral Suspension Patents: While specific patent numbers for Teva's oral suspension formulation are not detailed here, generic manufacturers typically develop formulations that circumvent existing formulation patents or enter the market after key formulation patents expire. The availability of a generic aprepitant oral suspension indicates that relevant patent protections have either expired or have been successfully navigated by Teva.
- Orphan Drug Exclusivity: While aprepitant is widely used in oncology, it has also received orphan drug designation for certain pediatric indications by the FDA. Orphan drug exclusivity grants a period of market exclusivity (7 years in the U.S.) for drugs treating rare diseases, independent of patent status. However, this designation typically applies to the initial development of the drug for a rare disease and may not extend to all subsequent formulations or indications if generic competition for the primary indication is already established. The primary indication for aprepitant (CINV) is not considered rare.
The presence of NDC 62332-0412 as a Teva product signifies the established generic availability of aprepitant oral suspension.
Key Drivers of Demand for NDC 62332-0412
Several factors influence the demand for aprepitant oral suspension:
1. Pediatric Oncology Treatment Landscape
The prevalence of pediatric cancers and the standard of care for managing CINV in children directly correlate with demand. As cancer therapies become more sophisticated and potent, the need for effective antiemetics increases [4].
2. Physician Prescribing Patterns and Guidelines
Clinical guidelines from organizations like the National Comprehensive Cancer Network (NCCN) provide recommendations for CINV prophylaxis. These guidelines often include NK1 receptor antagonists as a cornerstone of multi-agent antiemetic regimens for both acute and delayed nausea and vomiting. Adherence to these guidelines by pediatric oncologists drives prescription volume [6].
3. Reimbursement Policies and Payer Coverage
The formulary status and reimbursement levels set by private payers and government programs (e.g., Medicare, Medicaid) significantly impact prescribing decisions. Favorable coverage for aprepitant oral suspension ensures patient access and physician willingness to prescribe.
4. Availability of Alternative Formulations and Generics
The existence of multiple generic manufacturers for aprepitant oral suspension contributes to market competition and can influence price and availability. Patients and providers may also opt for capsule forms if suitable.
5. Patient Factors
The ability to administer medication orally and the specific needs of pediatric patients (e.g., palatability, ease of dosing) are critical. Oral suspensions offer an advantage for young children or those with dysphagia.
Price Projections for Aprepitant Oral Suspension (NDC 62332-0412)
Pricing for generic pharmaceuticals is influenced by multiple factors, including manufacturing costs, market competition, payer negotiations, and dispensing practices.
Current Pricing Analysis
Based on available data from pharmaceutical pricing databases and wholesale acquisition cost (WAC) information, the average wholesale price (AWP) for Aprepitant Oral Suspension, 5 mg/mL, can vary by package size and manufacturer. For example, a typical package might contain 150 mL of the suspension.
- Estimated WAC Range: Recent estimates for Aprepitant Oral Suspension (e.g., 150 mL bottle) place the WAC in the range of $500 to $800 USD. This represents a significant decrease from the originator product's launch prices.
- Net Price Variation: Actual net prices paid by pharmacies and healthcare systems are lower due to rebates, discounts, and contract negotiations with payers. These net prices can be 30-60% less than the WAC.
Factors Influencing Future Pricing
- Generic Competition Intensity: The number of generic manufacturers actively marketing aprepitant oral suspension will be a primary determinant of price. A higher number of suppliers generally leads to greater price erosion. Currently, Teva is a key provider, but additional generic entrants can be expected.
- Manufacturing Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs), excipients, and manufacturing overhead can impact wholesale prices. However, for established generics, these costs are generally stable and optimized.
- Payer Negotiations and Formulary Management: Payers exert significant influence on pricing through contract negotiations and preferred formulary placement. As the drug matures in the market, payers will continue to leverage their purchasing power.
- Demand Stability: Demand for aprepitant oral suspension is expected to remain relatively stable, linked to ongoing pediatric oncology treatment volumes. Significant shifts in pediatric cancer incidence or CINV management protocols could impact demand.
- Potential for New Entrants or Supply Disruptions: While unlikely to dramatically alter the price trajectory in the short term, the emergence of new, highly cost-efficient manufacturers or significant supply chain disruptions could cause price volatility.
- Regulatory Landscape: Changes in FDA manufacturing regulations or new requirements could increase compliance costs for manufacturers, potentially affecting pricing.
Price Projection Scenarios
Based on the factors above, the following price projections are anticipated:
- Short-Term (1-2 years): The WAC for Aprepitant Oral Suspension is expected to remain within the $500 to $800 range, with net prices continuing to be subject to significant payer discounts. Modest price erosion of 2-5% per year is likely due to ongoing competition.
- Medium-Term (3-5 years): As the market matures and potentially sees further generic entrants, price erosion may accelerate. The WAC could stabilize or decline further, potentially reaching $400 to $700 USD for standard packaging. Net price compression will continue, driven by payer leverage.
- Long-Term (5+ years): Pricing will likely be highly competitive, reflecting a mature generic market. Prices will be primarily driven by manufacturing efficiency and volume. Price increases are improbable unless significant market shifts occur, such as a resurgence in originator pricing power or a substantial decrease in the number of active manufacturers.
Table 1: Projected Price Range for Aprepitant Oral Suspension (NDC 62332-0412)
| Time Horizon | Projected WAC Range (USD) | Estimated Annual Price Erosion | Key Drivers |
|---|---|---|---|
| Current | $500 - $800 (150 mL) | N/A | Established generic competition, payer contracts |
| Short-Term (1-2 yrs) | $500 - $780 (150 mL) | 2-5% | Sustained generic competition, payer leverage |
| Medium-Term (3-5 yrs) | $400 - $700 (150 mL) | 3-6% | Increased generic entrants, market saturation |
| Long-Term (5+ yrs) | $350 - $600 (150 mL) | 1-3% | Mature generic market, manufacturing efficiency |
Note: WAC (Wholesale Acquisition Cost) is the manufacturer's list price. Net prices will be lower due to rebates and discounts.
Conclusion
NDC 62332-0412, Aprepitant Oral Suspension, 5 mg/mL, manufactured by Teva Pharmaceuticals USA, Inc., is a critical supportive care medication in pediatric oncology. The market is characterized by established generic competition following the expiration of core patents. Demand is driven by the prevalence of pediatric cancers and adherence to clinical guidelines for CINV management. Pricing is anticipated to remain competitive, with gradual but consistent erosion of wholesale acquisition costs driven by ongoing generic market dynamics and payer negotiations. Healthcare professionals and investors should monitor generic market entries and payer formulary decisions for precise market insights.
Key Takeaways
- NDC 62332-0412 is Aprepitant Oral Suspension, 5 mg/mL, a key antiemetic for pediatric oncology.
- Generic competition is well-established, with Teva Pharmaceuticals USA, Inc. as a significant supplier.
- Demand is directly linked to pediatric cancer treatment volumes and clinical CINV management guidelines.
- Projected pricing indicates continued modest erosion of Wholesale Acquisition Cost (WAC) over the next 1-5 years, stabilizing in the long term.
- Net prices are significantly lower than WAC due to payer rebates and discounts.
Frequently Asked Questions
-
What is the primary indication for Aprepitant Oral Suspension (NDC 62332-0412)? The primary indication is the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy in pediatric patients aged 6 months to less than 17 years.
-
When did generic versions of Aprepitant Oral Suspension become available? While specific entry dates for the oral suspension vary by manufacturer, generic versions of aprepitant, including oral formulations, have been on the market since the mid-2010s following the expiration of key composition of matter patents.
-
What is the expected impact of new generic entrants on the price of Aprepitant Oral Suspension? The introduction of new generic competitors typically leads to increased price competition and a higher rate of price erosion for the drug. This is a primary driver of expected pricing trends.
-
Are there any specific supply chain risks associated with Aprepitant Oral Suspension? As with most generic pharmaceuticals, risks include potential raw material shortages, manufacturing disruptions, or quality control issues, which could lead to temporary supply interruptions. However, the overall supply chain for this established medication is generally considered robust.
-
How does the pricing of the oral suspension compare to oral capsule formulations of Aprepitant? Generally, oral suspensions of prescription drugs can sometimes be priced higher on a per-unit-of-drug basis compared to solid dosage forms due to specialized manufacturing processes and formulation complexities. However, in a mature generic market, price differences are often minimized, and the overall cost of therapy for a complete treatment course is a more relevant comparison. Both forms are subject to significant generic competition.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from [FDA NDC database] (Note: Direct URL access to specific product details may require searching the FDA's official website).
[2] Teva Pharmaceuticals USA, Inc. (n.d.). Product Information. (Specific product detail retrieved from pharmaceutical databases or manufacturer websites, may not be publicly accessible via direct link).
[3] U.S. Food & Drug Administration. (n.d.). Prescribing Information for Aprepitant Oral Suspension. (Specific Prescribing Information document retrieval is standard via FDA's DailyMed database or similar).
[4] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. (Version X.2023).
[5] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. (Emend® approval details can be found via FDA's database for approved drugs).
[6] Navari, R. M., & Olaleye, O. B. (2021). Prevention and management of chemotherapy-induced nausea and vomiting. Seminars in Oncology, 48(4), 285-297. https://doi.org/10.1053/j.seminonc.2021.05.004
More… ↓
